These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 8548936)
1. Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate. Selby PL; Davies M; Marks JS; Mawer EB Clin Endocrinol (Oxf); 1995 Nov; 43(5):531-6. PubMed ID: 8548936 [TBL] [Abstract][Full Text] [Related]
2. Vitamin D intoxication and hypercalcaemia in an infant treated with pamidronate infusions. Ezgu FS; Buyan N; Gündüz M; Tümer L; Okur I; Hasanoglu A Eur J Pediatr; 2004 Mar; 163(3):163-5. PubMed ID: 14714183 [TBL] [Abstract][Full Text] [Related]
3. The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication. Lee DC; Lee GY J Toxicol Clin Toxicol; 1998; 36(7):719-21. PubMed ID: 9865241 [TBL] [Abstract][Full Text] [Related]
4. Hypercalcaemia due to sarcoidosis corrects with bisphosphonate treatment. Gibbs CJ; Peacock M Postgrad Med J; 1986 Oct; 62(732):937-8. PubMed ID: 3774726 [TBL] [Abstract][Full Text] [Related]
5. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. Coukell AJ; Markham A Drugs Aging; 1998 Feb; 12(2):149-68. PubMed ID: 9509293 [TBL] [Abstract][Full Text] [Related]
6. Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin. Ralston SH; Alzaid AA; Gardner MD; Boyle IT Br Med J (Clin Res Ed); 1986 Jun; 292(6535):1549-50. PubMed ID: 3087513 [TBL] [Abstract][Full Text] [Related]
7. Immobilization-related hypercalcaemia--a possible novel mechanism and response to pamidronate. Gallacher SJ; Ralston SH; Dryburgh FJ; Logue FC; Allam BF; Boyce BF; Boyle IT Postgrad Med J; 1990 Nov; 66(781):918-22. PubMed ID: 2267202 [TBL] [Abstract][Full Text] [Related]
8. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. Ralston SH; Gardner MD; Dryburgh FJ; Jenkins AS; Cowan RA; Boyle IT Lancet; 1985 Oct; 2(8461):907-10. PubMed ID: 2865417 [TBL] [Abstract][Full Text] [Related]
9. Hypercalcaemia in primary oxalosis: role of increased bone resorption and effects of treatment with pamidronate. Yamaguchi K; Grant J; Noble-Jamieson G; Jamieson N; Barnes ND; Compston JE Bone; 1995 Jan; 16(1):61-7. PubMed ID: 7742085 [TBL] [Abstract][Full Text] [Related]
10. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484 [TBL] [Abstract][Full Text] [Related]
11. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type. Body JJ; Dumon JC Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034 [TBL] [Abstract][Full Text] [Related]
12. Pamidronate treatment in acute vitamin D intoxication. Gurkan F; Davutoglu M; Bosnak M; Ece A; Dikici B; Bilici M; Haspolat K J Endocrinol Invest; 2004; 27(7):680-2. PubMed ID: 15505994 [TBL] [Abstract][Full Text] [Related]
13. Hypercalcemia and hyperosteolysis in vitamin D intoxication: effects of clodronate therapy. Rizzoli R; Stoermann C; Ammann P; Bonjour JP Bone; 1994; 15(2):193-8. PubMed ID: 8086237 [TBL] [Abstract][Full Text] [Related]
14. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Fitton A; McTavish D Drugs; 1991 Feb; 41(2):289-318. PubMed ID: 1709854 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134 [TBL] [Abstract][Full Text] [Related]
16. Hypercalcaemia in osteogenesis imperfecta treated with pamidronate. Williams CJ; Smith RA; Ball RJ; Wilkinson H Arch Dis Child; 1997 Feb; 76(2):169-70. PubMed ID: 9068314 [TBL] [Abstract][Full Text] [Related]
17. Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy. McIntyre HD; Cameron DP; Urquhart SM; Davies WE Postgrad Med J; 1989 Apr; 65(762):244-6. PubMed ID: 2594602 [TBL] [Abstract][Full Text] [Related]
18. Comparison of Treatment Regimens in Management of Severe Hypercalcemia Due to Vitamin D Intoxication in Children. Demir K; Döneray H; Kara C; Atay Z; Çetinkaya S; Çayır A; Anık A; Eren E; Uçaktürk A; Can Yılmaz G; Törel Ergür A; Kendirci M; Aycan Z; Bereket A; Aydın M; Orbak Z; Özkan B J Clin Res Pediatr Endocrinol; 2019 May; 11(2):140-148. PubMed ID: 30396880 [TBL] [Abstract][Full Text] [Related]
19. Aminohydroxypropylidene bisphosphonate (AHPrBP) treatment of severe immobilization hypercalcaemia in a young patient. Varache N; Audran M; Clochon P; Lortholary A; Bouachour G; Alquier P; Basle MF Clin Rheumatol; 1991 Sep; 10(3):328-32. PubMed ID: 1790647 [TBL] [Abstract][Full Text] [Related]
20. Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy. Wimalawansa SJ Clin Endocrinol (Oxf); 1994 Nov; 41(5):591-5. PubMed ID: 7828347 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]